Biogen Inc

BIIB

NASDAQ. Currency in USD

309.18 +16.75 ( +6.10% )

Real time prices: November 30

Market Cap.
44.54B
Beta (5Y monthly)
0.19
Price/Earnings
17.82
EPS (TTM)
17.03
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.10M
1y Target Est.
307.78
Day's Range
288.44
-
293.97
52 Week's Range
187.16
-
307.53

Historical Summary

Performance
EPS growth
Share Buybacks

About Biogen Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.biogen.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
146.89M
Employees
9610
Address
225 Binney Street, Cambridge, MA, United States, 02142
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Latest news

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 17 hours ago

Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY)...
By Zacks Investment Research - 20 hours ago

Dow ends over 700 points higher to exit bear market after Powell signals smaller interest-rate hikes ahead
Dow ends over 700 points higher to exit bear market after Powell signals smaller interest-rate hikes ahead

U.S. stocks finished sharply higher Wednesday after Fed Chair Powell said the central bank's pace...
By MarketWatch - 1 day ago

What to know about the Alzheimer’s drug data coming out this week
What to know about the Alzheimer’s drug data coming out this week

Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen...
By MarketWatch - 1 day ago

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the...
By Benzinga - 1 day ago

Dow down over 200 points as investors digest mixed economic data ahead of Powell speech
Dow down over 200 points as investors digest mixed economic data ahead of Powell speech

U.S. stocks traded mostly lower in midday trading Wednesday as traders look ahead to a...
By MarketWatch - 1 day ago

5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners

Results of a clinical trial point to a stable future for Eisai and Biogen's lecanemab...
By MarketWatch - 1 day ago

Dow down 200 points as investors eye Powell speech
Dow down 200 points as investors eye Powell speech

U.S. stocks move mostly lower Wednesday morning as traders look ahead to a speech from...
By MarketWatch - 1 day ago